These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 16502078)

  • 21. Clinical experience with darbepoietin alfa (NESP) in children undergoing hemodialysis.
    De Palo T; Giordano M; Palumbo F; Bellantuono R; Messina G; Colella V; Caringella AD
    Pediatr Nephrol; 2004 Mar; 19(3):337-40. PubMed ID: 14745634
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
    Attallah N; Osman-Malik Y; Frinak S; Besarab A
    Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Erythropoietin requirements increase following hospitalization in end-stage renal disease patients.
    Yaqub MS; Leiser J; Molitoris BA
    Am J Nephrol; 2001; 21(5):390-6. PubMed ID: 11684801
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Intravenous calcitriol in the treatment of the refractory secondary hyperparathyroidism of terminal chronic kidney failure].
    Almirall J; Torregrosa V; Arrizabalaga P; Cases A; Oliva J
    Med Clin (Barc); 1994 Mar; 102(9):325-8. PubMed ID: 8164458
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Australian haemodialysis patients on intravenous epoetin alfa or intravenous darbepoetin alfa: how do they compare?
    Pussell BA; Walker R;
    Nephrology (Carlton); 2007 Apr; 12(2):126-9. PubMed ID: 17371333
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Calcitriol increases burst forming unit-erythroid (BFU-E) in vitro proliferation in chronic uremia. Synergic effect with DNA recombinant erythropoietin (rHu-Epo)].
    Aucella F; Gatta G; Vigilante M; Scalzulli RP; Mantuano S; Carotenuto M; Stallone C
    Minerva Urol Nefrol; 2001 Mar; 53(1):1-5. PubMed ID: 11346713
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative effect of oral pulse and intravenous calcitriol treatment in hemodialysis patients: the effect on serum IL-1 and IL-6 levels and bone mineral density.
    Türk S; Akbulut M; Yildiz A; Gürbilek M; Gönen S; Tombul Z; Yeksan M
    Nephron; 2002 Feb; 90(2):188-94. PubMed ID: 11818704
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in predialysis chronic kidney disease patients with anemia.
    Papatheofanis FJ; McKenzie RS; Mody SH; Suruki RY; Piech CT
    Curr Med Res Opin; 2006 May; 22(5):837-42. PubMed ID: 16709305
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of parathyroidectomy on anemia and erythropoietin dosing in end-stage renal disease patients with hyperparathyroidism.
    Trunzo JA; McHenry CR; Schulak JA; Wilhelm SM
    Surgery; 2008 Dec; 144(6):915-8; discussion 919. PubMed ID: 19040997
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period.
    Silverberg DS; Blum M; Agbaria Z; Deutsch V; Irony M; Schwartz D; Baruch R; Yachnin T; Steinbruch S; Iaina A
    Clin Nephrol; 2001 Mar; 55(3):212-9. PubMed ID: 11316241
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Increased in vitro and ex vivo proliferation of erythroid precursors induced by calcitriol in chronic renal failure. Synergistic effect with rHuEPO].
    Aucella F; Gatta G; Vigilante M; Scalzulli RP; Mantuano S; Carotenuto M; Stallone C
    G Ital Nefrol; 2002; 19(2):137-42. PubMed ID: 12195411
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Erythropoietin-alpha dosage requirements in a provincial hemodialysis population: effect of switching from subcutaneous to intravenous administration.
    Raymond CB; Collins DM; Bernstein KN; Skwarchuk DE; Vercaigne LM
    Nephron Clin Pract; 2006; 102(3-4):c88-92. PubMed ID: 16282700
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The effectiveness of long-term treatment of severe secondary hyperparathyroidism with intravenous calcitriol].
    Nori G; Rossi G; Magarini C; Matocci GP
    Minerva Urol Nefrol; 1999 Sep; 51(3):171-9. PubMed ID: 10638183
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trends in anemia management among US hemodialysis patients.
    Coladonato JA; Frankenfield DL; Reddan DN; Klassen PS; Szczech LA; Johnson CA; Owen WF
    J Am Soc Nephrol; 2002 May; 13(5):1288-95. PubMed ID: 11961017
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adverse events in chronic hemodialysis patients receiving intravenous iron dextran--a comparison of two products.
    McCarthy JT; Regnier CE; Loebertmann CL; Bergstralh EJ
    Am J Nephrol; 2000; 20(6):455-62. PubMed ID: 11146312
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Calcitriol regresses cardiac hypertrophy and QT dispersion in secondary hyperparathyroidism on hemodialysis.
    Kim HW; Park CW; Shin YS; Kim YS; Shin SJ; Kim YS; Choi EJ; Chang YS; Bang BK
    Nephron Clin Pract; 2006; 102(1):c21-9. PubMed ID: 16166802
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of two iron gluconate treatment modalities in chronic hemodialysis patients: results of a randomized trial.
    Giordano A; Arrigo G; Lavarda F; Colasanti G; Petrini C
    J Nephrol; 2005; 18(2):181-7. PubMed ID: 15931646
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Severe hyperparathyroidism despite paricalcitol therapy: one-year follow-up.
    Shuja SB; Raja RM
    Adv Perit Dial; 2003; 19():231-5. PubMed ID: 14763069
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Durham Renal Osteodystrophy Study Group.
    Indridason OS; Quarles LD
    Kidney Int; 2000 Jan; 57(1):282-92. PubMed ID: 10620210
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advantages of adjusting the initial dose of intravenous calcitriol according to PTH levels.
    Rodríguez-García M; Fernández-Martín JL; de Castañeda JR; Hervás-Sánchez J; Cannata-Andía JB;
    Kidney Int Suppl; 2003 Jun; (85):S79-82. PubMed ID: 12753272
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.